---
document_datetime: 2023-09-21 19:44:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_en.pdf
document_name: respreeza-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9077445
conversion_datetime: 2025-12-17 09:07:09.156857
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                          | Route of administration   | Immediate Packaging                        | Content (concentration)        | Pack size                                             |
|------------------|-------------------|------------|----------------------------------------------|---------------------------|--------------------------------------------|--------------------------------|-------------------------------------------------------|
| EU/1/15/1006/001 | Respreeza         | 1000 mg    | Powder and solvent for solution for infusion | Intravenous use           | Powder: vial (glass) Solvent: vial (glass) | Powder: 1000 mg Solvent: 20 ml | 1 vial + 1 vial + 1 transfer set 20/20 (Mix2Vial set) |
| EU/1/15/1006/002 | Respreeza         | 4000 mg    | Powder and solvent for solution for infusion | Intravenous use           | Powder: vial (glass) Solvent: vial (glass) | Powder: 4000 mg Solvent: 76 ml | 1 vial + 1 vial + 1 transfer set 20/20 (Mix2Vial set) |
| EU/1/15/1006/003 | Respreeza         | 5000 mg    | Powder and solvent for solution for infusion | Intravenous use           | Powder: vial (glass) Solvent: vial (glass) | Powder: 5000 mg Solvent: 95 ml | 1 vial + 1 vial + 1 transfer set 20/20 (Mix2Vial set) |